Method for treating a disease associated with excessive...

Details Method for treating a disease associated with excessive... Method for treating a disease associated with excessive...

2005-05-24

2005-05-24

Spector, Lorraine (Department: 1646)

Drug, bio-affecting and body treating compositions

Lymphokine

Interleukin

C530S351000

Reexamination Certificate

active

06896880

ABSTRACT:
An osteoclastgenic inhibitory agent which comprises an interleukin-18 and/or its functional equivalent. The agent can be arbitrarily used as an ingredient for cell culture and agents for regulating bone resorption and for osteoclast-related diseases, directed to treat and/or prevent hypercalcemia, osteoclastoma, osteoporosis, etc.

REFERENCES:
patent: 4588585 (1986-05-01), Mark et al.
patent: 5776731 (1998-07-01), Parnet et al.
patent: 5912324 (1999-06-01), Okamura et al.
patent: 6156301 (2000-12-01), Namen et al.
patent: 6207641 (2001-03-01), Torigoe et al.
patent: 6476197 (2002-11-01), Yamamoto et al.
patent: 0 712 931 (1996-05-01), None
patent: 0 712 931 (1996-05-01), None
patent: 0 721 780 (1996-07-01), None
patent: 0845530 (1998-06-01), None
patent: 08-027189 (1996-01-01), None
patent: 08-193098 (1996-07-01), None
patent: 08-231598 (1996-09-01), None
patent: 09-289896 (1997-11-01), None
patent: 9744468 (1997-11-01), None
Merck Manual, 17th ed., “Hypercalcemia”, p. 145-147.*
Dorland's Illustrated Medical Dictionary, 29th ed., W.B. Saunders Company, p. 1750.*
Dinarello et al. Overview of IL-18: more than an interferon-g inducing factor. J. Leukocyte Biology, 1998, 63:658-664.*
Kohno et al. Molecule of the month, IL-18, a cytokine which resembles IL-1 structurally and IL-12 functionally but exerts its effect independently of both. Clin. Immuno. Immunopath., 1998, 86: 11-15.*
Udagawa et al. IL-18 is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-g to inhibit osteoclast formation. J. Exp. Med., Mar. 1997, 185:1005-1012.*
Martin et al.,Crit. Rev. Eukaryot. Gene Express812:107 (1998) (Abstract).
Udagawa et al.,J. Exp. Med.,185(6)1005-1012 (1998).
XP 002038817, Beier et al.
Martin et al.,Crit. Rev. Eukaryot. Gene Express,8(2)107 (1998) Abstract.
Udagaua et al.,J. Exp. Med.,185(6)1005-12 (1997).
Horwood et al., et al.,J. Clin. Invest.,585 (1998).
Henco, K. et al., “Structural relationship of human interferon alpha genes and pseudogenes.”,J.Mol.Biol.,vol. 185, pp. 227-260 (1985).
Udagawa, N. et al., “Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors.”,J. Exp.Med.,pp. 1461-1468 (1995).
Martin, T.J. et al., “Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity.”,J.Cell.Biochem.,vol. 56, pp 357-366 (1994).
Ushio, S. et al., “Cloning of the cDNA for human IFN-gamma-inducing factor, expression inEscherichia coli, and studies on the biologic activities of the protein.”,J.Immuno.,vol. 96, pp. 4274-4279 (1996).
Okamura, H. et al., “Cloning of a new cytokine that induces IFN-gamma production by T cells.”,Letters to Nature,vol. 378, pp. 88-91 (1995).
Laemmli, U.K., “Cleavage of structural proteins during the assembly of the head of bacteriophage T4.”,Nature, vol. 227, pp. 680-683 (1970).
Roodman, G., “Advances in bone biology: the osteoclast”,Endocrine Reviews,vol. 17, pp. 308-332 (1996).
Excerpt Translation of:Nikkei Biotechnology Report1996, pp. 498-499 (1995).

Affiliated with

Also associated with

Rating

Method for treating a disease associated with excessive... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for treating a disease associated with excessive..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating a disease associated with excessive... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3440616